Name: Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Co-prescribed/Concomitant therapies
Published: 2026-09-21T21:42:40-04:00

Product information and disease description Product description Product information

Co-prescribed/Concomitant therapies

3 evidence topics · 2 sources

Concomitant therapies restricted in the phase 3 trial

“Afamelanotide within 3 months” (opens the source at this quote in a new tab)
“Chronic treatment with any scheduled analgesic agents including, but not limited to, opioids and opioid derivatives such as morphine, hydrocodone, oxycodone, fentanyl, or their combination with other unscheduled analgesics or non-steroidal anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4 weeks.” (opens the source at this quote in a new tab)
“Antioxidant agents within 4 weeks, at doses which, in the opinion of the Investigator, may affect study endpoints (including but not limited to beta-carotene, cysteine, pyridoxine).” (opens the source at this quote in a new tab)

Sunscreen use permitted alongside treatment

“Use of sunscreens with zinc oxide. Note: Sunscreens without zinc oxide are allowed, however their use, in frequency, quantity and body surface area should be maintained relatively stable throughout the duration of the study.” (opens the source at this quote in a new tab)

Background preventive measures that continue during treatment

“Current approaches to the management of EPP and XLP are primarily limited to preventive measures, including sun avoidance and use of protective clothing and sunscreens, posing a substantial burden to patients by requiring significant lifestyle adjustments” (opens the source at this quote in a new tab)